MedPage Today

Drug Combo Shows Benefits in Fit Patients With Acute Myeloid Leukemia

ORLANDO -- Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit adults with acute myeloid leukemia (AML) compared with conventional induction ...
ascopubs.org

Induction pembrolizumab plus cisplatin and 5-FU chemotherapy followed by chemoradiotherapy in locally advanced squamous cell cancer of oropharynx, hypopharynx or larynx ...

Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): An open-label, single-arm, phase 2 study. This is an ASCO Meeting Abstract from ...
The American Journal of Managed Care

Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML

Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction chemotherapy in AML patients. The study highlighted reduced hospital stays, ...
Cure Today

Azacitidine Plus Venclexta Superior to Chemo in Acute AML

Azacitidine/Venclexta improved EFS and quality of life compared to induction chemotherapy in fit AML patients, with a 39% risk reduction in disease progression or death. The PARADIGM trial showed a ...
ascopubs.org

The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab ...

ctDNA-based MRD detection in unresectable NSCLC undergoing curatively intended chemoradiotherapy and durvalumab. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...